Vaso-occlusive crisis (VOC) is the most common complication of sickle cell disease (SCD), characterized by severe, unrelenting bone pain caused by tissue ischemia from microvascular occlusion by sickled red blood cells. [1-2] Pain episodes are often preceded by a 1–2 day prodromal phase of fatigue and diffuse body aches, with peak intensity on days 3–7. [1] Patient report is the criterion standard for diagnosis — no objective signs or laboratory values can confirm or rule out a pain crisis. [1][3]
1. History
- Location, quality, severity: Ask where the pain is, whether it is typical of prior crises, and rate severity (NRS). Most common sites in decreasing frequency: upper back, left arm, legs, chest, lower back [4]
- Timing and onset: Acute vs. gradual; duration; prodromal symptoms (fatigue, diffuse aches 1–2 days prior) [1]
- Triggers: Cold exposure, dehydration, infection, physical exhaustion, emotional stress, hypoxia, menstruation, pregnancy, alcohol, obstructive sleep apnea [5-6]
- Home management attempted: Oral analgesics taken (NSAIDs, opioids), hydration, heat application, and whether these measures failed [2][7]
- Prior crisis pattern: Frequency of crises, typical locations, usual effective opioid doses, prior hospitalizations, individualized pain plan on file [3][8]
- Associated symptoms: Fever, cough, dyspnea, chest pain, abdominal pain, neurologic symptoms, priapism, hematuria [3]
- Important negatives: No trauma, no focal weakness, no vision changes, no urinary symptoms
2. Alarm Features
- Fever ≥38.3°C — signals possible sepsis in functionally asplenic patients; requires urgent blood cultures and empiric antibiotics [2]
- Chest pain, dyspnea, tachypnea, hypoxemia — concern for acute chest syndrome (ACS), the leading cause of death in adults with SCD [1]
- Acute neurologic deficits (hemiparesis, aphasia, seizures, altered mental status) — presume stroke until proven otherwise; requires emergent exchange transfusion [2][9]
- Rapidly increasing oxygen requirement or declining hemoglobin/platelet count during a pain episode — heralds multiorgan failure [7]
- Abdominal distension with acute splenic enlargement — splenic sequestration crisis, can progress to cardiovascular collapse [2]
- Priapism >4 hours — urologic emergency requiring aspiration/irrigation [3]
- Diffuse (multifocal) pain, nocturnal onset, and elevated CRP are early risk factors for progression to ACS [10]
3. Medications
Acute Treatment:
- Parenteral opioids (morphine or hydromorphone) — first dose within 60 minutes of ED arrival per ASH/NHLBI guidelines; reassess and redose every 30–60 minutes [8][11]
- Individualized dosing (based on home opioid intake and prior effective doses) is preferred over weight-based dosing — associated with lower admission rates (40% vs. 58%) [1][8]
- NSAIDs — ketorolac IV or ibuprofen PO as adjuncts to reduce inflammation and augment opioid analgesia [2]
- Acetaminophen — multimodal adjunct [12]
- Subanesthetic ketamine — for opioid-refractory pain in the inpatient setting [1-2]
- Intranasal fentanyl — useful for rapid initial analgesia, especially in pediatrics [11]
Contraindicated/Cautions:
- Meperidine (Demerol) — avoid due to seizure risk from normeperidine accumulation
- Excessive IV fluids — maintain euvolemia; overhydration can precipitate ACS and pulmonary edema [2]
- Supplemental O₂ — not routine unless hypoxemic [1]
- RBC transfusion — not indicated for uncomplicated pain crisis [1][7]
Disease-Modifying (Outpatient):
- Hydroxyurea — reduces VOC frequency; should be continued during admission [2]
- L-glutamine, crizanlizumab (P-selectin inhibitor) — FDA-approved to reduce VOC frequency [2][13]
4. Diet
- Aggressive oral hydration when tolerated; IV fluids to maintain euvolemia if unable to drink [2]
- Avoid dehydration — a known VOC trigger [5]
- No specific dietary restrictions during acute crisis; ensure adequate caloric intake
- Long-term: daily folic acid supplementation recommended [2]
5. Review of Systems
- Respiratory: Cough, dyspnea, pleuritic chest pain (ACS screening) [7]
- Neurologic: Headache, vision changes, focal weakness, speech difficulty (stroke screening) [2]
- GI: Nausea, vomiting, abdominal pain, jaundice (hepatic sequestration, cholecystitis) [4]
- GU: Hematuria, priapism, decreased urine output (renal complications) [3]
- Constitutional: Fever, fatigue, dizziness, pallor (infection, aplastic crisis, splenic sequestration) [4]
- MSK: Joint swelling, tenderness (avascular necrosis, osteomyelitis) [1]
6. Collateral History and Family History
- Individualized pain plan — check EHR for patient-specific opioid dosing protocols developed by hematologist [3][8]
- Baseline hemoglobin and reticulocyte count — essential for comparison during acute episodes
- SCD genotype (HbSS, HbSC, Sβ⁰, Sβ⁺) — HbSS and Sβ⁰ are generally more severe [7]
- Hydroxyurea adherence and current disease-modifying therapy
- Transfusion history — alloantibody status, prior delayed hemolytic transfusion reactions [14]
- Family history: SCD is autosomal recessive; family members may carry trait or disease [7]
- Social context: Stigma and implicit bias are well-documented barriers to adequate pain management in SCD [7-8]
7. Risk Factors
- Patient factors: Hypoxia, infection, fever, acidosis, dehydration, pregnancy, menstruation, obstructive sleep apnea, anxiety/depression, physical exhaustion, alcohol [5]
- Environmental: Cold temperatures, high wind speed, humidity extremes [5]
- Hematologic: Higher WBC/neutrophil counts, lower fetal hemoglobin, higher baseline hemoglobin (paradoxically increases viscosity) [2][5]
- Comorbidities: Asthma/reactive airway disease (increases ACS risk), diabetes, prior ACS episodes [5][15]
- Genetic: HbSS genotype, absence of co-inherited α-thalassemia trait, low HbF expression [1-2]
8. Differential Diagnosis
- Acute chest syndrome — new infiltrate + chest pain/hypoxemia/tachypnea/fever; can develop 2–4 days into a VOC [1-2]
- Osteomyelitis (especially Salmonella or Staphylococcus) — focal bone pain with fever; may mimic VOC [1]
- Avascular necrosis — hip or shoulder pain; chronic but can present acutely
- Splenic sequestration — acute LUQ pain, rapidly enlarging spleen, acute anemia [2]
- Aplastic crisis (parvovirus B19) — severe anemia with low reticulocyte count
- Stroke — acute neurologic deficits [2][9]
- Pulmonary embolism — chest pain and dyspnea; SCD is a hypercoagulable state
- Cholecystitis/cholelithiasis — pigmented gallstones common in chronic hemolysis
- Sepsis — functional asplenia predisposes to encapsulated organisms [1]
- Priapism — ischemic penile pain
- Renal papillary necrosis — flank pain and hematuria
9. Past Medical History
- Prior VOC frequency and severity; prior hospitalizations and ICU admissions
- History of ACS, stroke, splenic sequestration, avascular necrosis
- Transfusion history and alloantibody status (critical before any transfusion) [14]
- Surgical history: splenectomy, cholecystectomy, hip replacement
- Chronic complications: pulmonary hypertension, chronic kidney disease, retinopathy, leg ulcers [1]
- Current disease-modifying therapy and adherence (hydroxyurea, crizanlizumab, L-glutamine)
- Chronic pain status and home opioid regimen
10. Physical Exam
- Vitals: Temperature (fever ≥38.3°C is a red flag), HR, BP, RR, SpO₂ (baseline may be lower in SCD; new desaturation is concerning) [14]
- General: Degree of distress, pallor, jaundice/scleral icterus
- Lungs: Auscultate for crackles, decreased breath sounds, wheezing (ACS) [7]
- Abdomen: Spleen size (sequestration), RUQ tenderness (cholecystitis), hepatomegaly
- Extremities/MSK: Point tenderness, swelling, warmth (osteomyelitis vs. infarction), joint effusions
- Neuro: Focused exam — strength, speech, cranial nerves, mental status (stroke screening) [2]
- Skin: Leg ulcers, pallor of mucous membranes
- GU (if indicated): Priapism assessment
11. Lab Studies
Initial labs (guided by clinical scenario, not routine for uncomplicated VOC):
- CBC with differential and reticulocyte count — compare to baseline; drop in Hgb or reticulocytes suggests aplastic crisis or sequestration [2][16]
- Type and screen — essential if transfusion may be needed; extended phenotype matching required
- Comprehensive metabolic panel — renal function (SCD nephropathy), hepatic function, electrolytes
- LDH, indirect bilirubin, haptoglobin — hemolysis markers [17]
- Blood cultures — if febrile (≥38.3°C) [2]
- Urinalysis — if urinary symptoms or hematuria
Important pearl: ASH endorses avoiding daily laboratory draws in clinically stable admitted patients, as phlebotomy contributes to anemia [1]
During VOC, expect: Lower Hgb than baseline, elevated WBC/neutrophils, elevated LDH, CRP, ferritin, and bilirubin [17]
12. Imaging
- Chest X-ray — obtain if fever, respiratory symptoms, chest pain, or hypoxemia to evaluate for ACS (new pulmonary infiltrate); may be normal initially [2][7]
- CT chest — if high suspicion for PE or ACS with negative CXR [14]
- Lung ultrasound — emerging modality for ACS evaluation [14]
- Brain CT (non-contrast) — emergent if any acute neurologic symptoms; followed by MRI/MRA when available [2]
- Abdominal imaging — if concern for splenic sequestration, cholecystitis, or hepatic sequestration
- Imaging is NOT needed for routine uncomplicated VOC — no imaging can confirm or quantify pain [3]
13. Special Tests
- Transcranial Doppler (TCD) — annual screening in children ages 2–16 to assess stroke risk (not acute ED test) [9][18]
- Incentive spirometry — should be initiated in all admitted patients with thoracoabdominal pain to prevent ACS [7]
- Hemoglobin electrophoresis — confirms genotype if not previously documented
- Point-of-care ultrasound — assess for splenic enlargement, pleural effusion, cardiac function
- Echocardiography — if concern for pulmonary hypertension or cardiac dysfunction [14]
14. ECG
- Obtain if chest pain — to evaluate for cardiac ischemia, especially in adults with SCD who may have cardiomyopathy [16]
- The ACC/AHA recommends ECG, troponin, CBC with differential, reticulocyte count, CXR, and cultures for all adults with SCD presenting with chest pain concerning for ACS [16]
- Chronic findings in SCD may include LVH, nonspecific ST-T changes from chronic anemia
- Acute ST changes or new arrhythmias warrant cardiology consultation
15. Assessment
- VOC is a clinical diagnosis based on patient report; there is no confirmatory test [1][3]
- Severity stratification is based on pain intensity, response to initial analgesia, vital sign abnormalities, and presence of concurrent complications
- Typical presentation: Severe bone pain in extremities, back, or chest; often in a pattern familiar to the patient
- Atypical/concerning presentations: Diffuse multifocal pain (higher ACS risk), abdominal pain (sequestration, cholecystitis), headache (stroke), chest pain with hypoxemia (ACS) [10]
- Complications to anticipate: ACS develops in ~15% of patients admitted for VOC, typically days 2–4 of hospitalization; multiorgan failure is rare but rapidly fatal [1][15]
16. Treatment Plan
Initial Stabilization (ED):
- Rapid triage — ESI level 2 [3]
- First parenteral opioid within 60 minutes of arrival [8][11]
- Multimodal analgesia: parenteral opioid (morphine 0.1–0.15 mg/kg IV or hydromorphone) + ketorolac 15–30 mg IV + acetaminophen [2][12]
- Reassess pain every 30–60 minutes; redose opioids as needed [11]
- IV fluids at maintenance rate for euvolemia — avoid overhydration [2]
- Incentive spirometry q1–2h while awake if chest/back/abdominal pain [7]
If Admitted:
- PCA (patient-controlled analgesia) with morphine or hydromorphone [2]
- Continue home long-acting opioids (including methadone) to prevent withdrawal [3]
- Continue hydroxyurea and other disease-modifying therapies
- Subanesthetic ketamine or regional anesthesia for refractory pain [1-2]
- Integrative therapies: massage, virtual reality, heat application [1]
- Monitor for ACS development — daily respiratory assessment, incentive spirometry [7]
Not Recommended for Routine VOC:
- Supplemental O₂ (unless SpO₂ below patient's baseline) [1]
- RBC transfusion (reserve for ACS, stroke, acute anemia, sequestration) [1][7]
- Meperidine [2]
The following figure illustrates a multimodal pain protocol for VOC management in the ED and inpatient settings:
17. Disposition
Admission Criteria:
- Pain uncontrolled after 2–3 doses of parenteral opioids in ED
- Fever ≥38.3°C requiring IV antibiotics and observation [2]
- New or worsening hypoxemia, respiratory symptoms (ACS concern) [7]
- Acute neurologic symptoms [2]
- Significant drop in hemoglobin from baseline
- Splenic sequestration or hemodynamic instability
- Concurrent complications (priapism, renal failure, hepatic crisis)
ICU Admission:
- ACS with progressive hypoxemia or need for exchange transfusion [14]
- Stroke requiring emergent exchange transfusion [2]
- Multiorgan failure [1]
- Hemodynamic instability from splenic sequestration
Discharge Criteria:
- Pain controlled on oral analgesics for ≥4–6 hours
- Tolerating oral fluids and medications
- Stable vital signs, no fever, adequate oxygenation
- No signs of ACS or other complications
- Reliable follow-up and access to oral analgesics at home
Observation:
Specialist Consultation:
- Hematology — for all admitted patients; for exchange transfusion decisions
- Pain service/anesthesia — for refractory pain (ketamine, regional blocks) [12]
- Neurosurgery — for cerebral hemorrhage [2]
- Urology — for priapism >4 hours
- Pulmonology/ICU — for severe ACS
18. Follow Up / Return Precautions
Follow-up Timing:
- Hematology follow-up within 1–2 weeks of discharge
- PCP follow-up within 1 week
- If frequent VOCs (≥3/year), discuss optimization of disease-modifying therapy (hydroxyurea dose escalation, crizanlizumab, L-glutamine) [2]
Return Precautions — Instruct patients to return immediately for:
- Fever ≥38.3°C (101°F) [2]
- Chest pain, shortness of breath, or cough (ACS) [7]
- Weakness on one side, trouble speaking, severe headache (stroke) [2]
- Worsening or uncontrolled pain despite home medications
- Abdominal swelling or pain (splenic sequestration)
- Priapism lasting >2 hours
- Increasing pallor, dizziness, or fatigue (worsening anemia)
Patient Counseling:
- Avoid known triggers: cold exposure, dehydration, overexertion, smoking [5]
- Maintain hydration and take medications as prescribed
- Use incentive spirometer at home if provided
- SCD patients are not more likely to develop opioid addiction than the general population — this is an important point to address given widespread stigma [1]
Expected Recovery:
- Typical VOC resolves over 5–7 days with peak intensity on days 3–7 [1]
- Median hospital stay approximately 3.5 days with multimodal protocols [12]
References
1. Sickle Cell Disease: A Review. — Kavanagh PL, Fasipe TA, Wun T. The Journal of the American Medical Association. 2022.
2. Sickle Cell Disease: A Review. — Kavanagh PL, Fasipe TA, Wun T. The Journal of the American Medical Association. 2022.
3. Sickle Cell Disease: A Review. — Kavanagh PL, Fasipe TA, Wun T. The Journal of the American Medical Association. 2022.
4. Sickle Cell Disease. — Bender MA, Carlberg K GeneReviews® [Internet]. 2025.
5. Sickle Cell Disease. — Bender MA, Carlberg K GeneReviews® [Internet]. 2025.
6. Evidence-Based Management of Sickle Cell Disease: Expert Panel Report, 2014. — National Heart, Lung, and Blood Institute. 2014.
7. Evidence-Based Management of Sickle Cell Disease: Expert Panel Report, 2014. — National Heart, Lung, and Blood Institute. 2014.
8. Inhaled Nitric Oxide for Treating Pain Crises in People With Sickle Cell Disease. — Aboursheid T, Albaroudi O, Alahdab F. The Cochrane Database of Systematic Reviews. 2022.
9. Inhaled Nitric Oxide for Treating Pain Crises in People With Sickle Cell Disease. — Aboursheid T, Albaroudi O, Alahdab F. The Cochrane Database of Systematic Reviews. 2022.
10. The vaso‐occlusive pain crisis in sickle cell disease: Definition, pathophysiology, and management. — Darbari DS, Sheehan VA, Ballas SK. European Journal of Haematology. 2020.
11. The vaso‐occlusive pain crisis in sickle cell disease: Definition, pathophysiology, and management. — Darbari DS, Sheehan VA, Ballas SK. European Journal of Haematology. 2020.
12. Role of Menstrual Bleeding Assessments in Sickle Cell Clinics. — Rush G, Mohamed RE, Moffatt-Bazile K, et al. JAMA Network Open. 2025.
13. Role of Menstrual Bleeding Assessments in Sickle Cell Clinics. — Rush G, Mohamed RE, Moffatt-Bazile K, et al. JAMA Network Open. 2025.
14. Health Supervision for Children and Adolescents With Sickle Cell Disease: Clinical Report. — Yates AM, Aygun B, Nuss R, Rogers ZR. Pediatrics. 2024.
15. Health Supervision for Children and Adolescents With Sickle Cell Disease: Clinical Report. — Yates AM, Aygun B, Nuss R, Rogers ZR. Pediatrics. 2024.
16. Difference in Median Times to Pain Medication Between Adult Patients With a Diagnosis of Sickle Cell Disease (SCD) With Vaso-Occlusive Episode (VOE) and Renal Colic Methodology Report. — Kyle Campbell PharmD, Hayley Dykhoff MSPH, Mariana Grass DHSc MPH, et al American Society of Hematology (2025). 2025.
17. Difference in Median Times to Pain Medication Between Adult Patients With a Diagnosis of Sickle Cell Disease (SCD) With Vaso-Occlusive Episode (VOE) and Renal Colic Methodology Report. — Kyle Campbell PharmD, Hayley Dykhoff MSPH, Mariana Grass DHSc MPH, et al American Society of Hematology (2025). 2025.
18. Sickle Cell Disease. — Ware RE, de Montalembert M, Tshilolo L, Abboud MR. Lancet. 2017.
19. Sickle Cell Disease. — Ware RE, de Montalembert M, Tshilolo L, Abboud MR. Lancet. 2017.
20. Early Risk Factors for Acute Chest Syndrome in Sickle Cell Anemia: A Pediatric Study. — Condé M, Bouvier F, Brat R, et al. PloS One. 2025.
21. Early Risk Factors for Acute Chest Syndrome in Sickle Cell Anemia: A Pediatric Study. — Condé M, Bouvier F, Brat R, et al. PloS One. 2025.
22. Opioid Timeliness in the Emergency Department and Hospitalizations for Acute Sickle Cell Pain. — Gwarzo I, Coleman KD, McKinley K, et al. JAMA Pediatrics. 2025.
23. Opioid Timeliness in the Emergency Department and Hospitalizations for Acute Sickle Cell Pain. — Gwarzo I, Coleman KD, McKinley K, et al. JAMA Pediatrics. 2025.
24. A multimodal pain protocol for treatment of vaso‐occlusive crisis in patients with sickle cell disease: Implementation and evaluation. — Admiraal M, van Daalen J, Ritt MWJ, et al. European Journal of Haematology. 2023.
25. A multimodal pain protocol for treatment of vaso‐occlusive crisis in patients with sickle cell disease: Implementation and evaluation. — Admiraal M, van Daalen J, Ritt MWJ, et al. European Journal of Haematology. 2023.
26. FDA Orange Book. — FDA Orange Book. 2026.
27. FDA Orange Book. — FDA Orange Book. 2026.
28. Guidelines for the Management of Emergencies and Critical Illness in Pediatric and Adult Patients With Sickle Cell Disease. — Mekontso Dessap A, Dauger S, Khellaf M, et al. Annals of Intensive Care. 2025.
29. Guidelines for the Management of Emergencies and Critical Illness in Pediatric and Adult Patients With Sickle Cell Disease. — Mekontso Dessap A, Dauger S, Khellaf M, et al. Annals of Intensive Care. 2025.
30. Risk Factors for Acute Chest Syndrome Among Children With Sickle Cell Anemia Hospitalized for Vaso-Occlusive Crises. — Alghamdi FA, Al-Kasim F, Alshhada F, et al. Scientific Reports. 2024.
31. Risk Factors for Acute Chest Syndrome Among Children With Sickle Cell Anemia Hospitalized for Vaso-Occlusive Crises. — Alghamdi FA, Al-Kasim F, Alshhada F, et al. Scientific Reports. 2024.
32. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. — Gulati M, Levy PD, Mukherjee D, et al. Journal of the American College of Cardiology. 2021.
33. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. — Gulati M, Levy PD, Mukherjee D, et al. Journal of the American College of Cardiology. 2021.
34. Inflammatory Markers in Sickle Cell Disease During Vaso-Occlusive Crisis. — Meher KK, Mohanty PK, Meher S. Blood Cells, Molecules & Diseases. 2026.
35. Inflammatory Markers in Sickle Cell Disease During Vaso-Occlusive Crisis. — Meher KK, Mohanty PK, Meher S. Blood Cells, Molecules & Diseases. 2026.
36. Management of Sickle Cell Disease: Recommendations From the 2014 Expert Panel Report. — Yawn BP, John-Sowah J. American Family Physician. 2015.
37. Management of Sickle Cell Disease: Recommendations From the 2014 Expert Panel Report. — Yawn BP, John-Sowah J. American Family Physician. 2015.